Soleno Stock Delisted From Nasdaq After $2.9 Billion Neurocrine Deal
Neurocrine Biosciences completed its $2.9 billion cash acquisition of Soleno Therapeutics, delisting Soleno from Nasdaq after a $53-per-share payout. The merger closed May 18, following a tender offer that secured 88.9% of Soleno shares. VYKAT XR, Soleno’s FDA-approved drug for Prader-Willi syndrome, generated $190 million in 2025 revenue. Nasdaq will next open after Memorial Day on Tuesday.